망막 생물제제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global Retinal Biologics Market, offering an in-depth analysis of key market dynamics, including growth drivers, trends, opportunities, and challenges. This detailed report provides insights into the market structure and growth potential over the forecast period.

Key Insights:

• Retinal Biologics Market Size (2024E): US$24.9 billion
• Projected Market Value (2031F): US$42.9 billion
• Global Market Growth Rate (CAGR 2024 to 2031): 8.1%

Retinal Biologics Market - Report Scope:

Retinal biologics are bioengineered substances used to treat persistent retinal disorders such as age-related macular degeneration (AMD) and diabetic retinopathy. These biologics are derived from living organisms, including microbes, animal cells, or plant cells, and are typically administered through ocular drug delivery methods. The increasing prevalence of retinal diseases worldwide, coupled with the growing elderly population, is driving the market's growth.

Market Growth Drivers:

Several key factors are driving the growth of the global Retinal Biologics Market. The rising prevalence of retinal disorders, such as AMD and diabetic retinopathy, and the growing elderly population worldwide are significant contributors. Moreover, the increasing adoption of biologics like VEGF-A antagonists and TNF-a inhibitors for targeted treatments is further propelling market growth.

Market Restraints:

Despite the growth potential, the Retinal Biologics Market faces challenges such as high development and manufacturing costs, stringent regulatory processes, and side effects associated with biologics. These factors can hinder market growth by limiting accessibility and increasing the price of retinal biologic treatments.

Market Opportunities:

The Retinal Biologics Market presents substantial growth opportunities through innovations in ocular drug delivery methods and the development of non-toxic, eco-friendly biologics. The introduction of autophagy modulation in retinal treatments also offers promising prospects for new therapies.

Key Questions Answered in the Report:

• What are the primary factors driving the global Retinal Biologics Market?
• Which regions are witnessing the highest adoption of retinal biologics, and what trends are influencing this growth?
• How are advancements in ocular drug delivery impacting the competitive landscape?
• Who are the leading players in the Retinal Biologics Market, and what strategies are they implementing to maintain their market positions?
• What are the emerging trends and future prospects in the global Retinal Biologics Market?

Competitive Intelligence and Business Strategy:

Leading players in the Retinal Biologics Market, such as Spark Therapeutics, F. Hoffmann-La Roche, and Regeneron Pharmaceuticals, are investing in research and development to introduce innovative biologic therapies. Collaborations with biotech firms and healthcare institutions are crucial for product development and market expansion. Addressing regulatory hurdles and ensuring the safety and efficacy of biologics will help companies maintain a competitive edge.

Key Companies Profiled:

• Spark Therapeutics, Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• AbbVie Inc.
• Amgen Inc.
• Novartis Pharma AG
• MeiraGTx Limited
• Oxurion NV
• Santen Pharmaceutical Co., Ltd.
• Bayer AG
• Bausch Health Companies Inc.
• Merck & Co., Inc.
• Adverum Biotechnologies
• SemaThera Inc.

Retinal Biologics Market Segmentation:

By Product:

• VEGF-A Antagonists
• TNF-a Inhibitors

By Indication:

• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

By Distribution Channel:

• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

By Region:

• North America
• Europe
• Asia Pacific
• The Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Retinal Biologics Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Value Chain Analysis
• 3.3. Key Deals and Mergers
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
• 4.3. Global Retinal Biologics Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 4.3.3.1. VEGF-A Antagonists
    • 4.3.3.2. TNF-a Inhibitors
• 4.4. Market Attractiveness Analysis: Drug Class
• 4.5. Global Retinal Biologics Market Outlook: Indication
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
    • 4.5.3.1. Macular Degeneration
    • 4.5.3.2. Diabetic Macular Edema
    • 4.5.3.3. Diabetic Retinopathy
    • 4.5.3.4. Uveitis
    • 4.5.3.5. Others
• 4.6. Market Attractiveness Analysis: Indication
• 4.7. Global Retinal Biologics Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Institutional Sales
    • 4.7.3.2. Retail Pharmacies
    • 4.7.3.3. Mail Order Pharmacies
    • 4.7.3.4. Retail Sales
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Retinal Biologics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Indication
  • 6.2.4. By Distribution Channel
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 6.4.1. VEGF-A Antagonists
  • 6.4.2. TNF-a Inhibitors
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 6.5.1. Macular Degeneration
  • 6.5.2. Diabetic Macular Edema
  • 6.5.3. Diabetic Retinopathy
  • 6.5.4. Uveitis
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.6.1. Institutional Sales
  • 6.6.2. Retail Pharmacies
  • 6.6.3. Mail Order Pharmacies
  • 6.6.4. Retail Sales
• 6.7. Market Attractiveness Analysis

7. Europe Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Indication
  • 7.2.4. By Distribution Channel
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 7.4.1. VEGF-A Antagonists
  • 7.4.2. TNF-a Inhibitors
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 7.5.1. Macular Degeneration
  • 7.5.2. Diabetic Macular Edema
  • 7.5.3. Diabetic Retinopathy
  • 7.5.4. Uveitis
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.6.1. Institutional Sales
  • 7.6.2. Retail Pharmacies
  • 7.6.3. Mail Order Pharmacies
  • 7.6.4. Retail Sales
• 7.7. Market Attractiveness Analysis

8. East Asia Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Indication
  • 8.2.4. By Distribution Channel
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 8.4.1. VEGF-A Antagonists
  • 8.4.2. TNF-a Inhibitors
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 8.5.1. Macular Degeneration
  • 8.5.2. Diabetic Macular Edema
  • 8.5.3. Diabetic Retinopathy
  • 8.5.4. Uveitis
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.6.1. Institutional Sales
  • 8.6.2. Retail Pharmacies
  • 8.6.3. Mail Order Pharmacies
  • 8.6.4. Retail Sales
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Indication
  • 9.2.4. By Distribution Channel
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 9.4.1. VEGF-A Antagonists
  • 9.4.2. TNF-a Inhibitors
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 9.5.1. Macular Degeneration
  • 9.5.2. Diabetic Macular Edema
  • 9.5.3. Diabetic Retinopathy
  • 9.5.4. Uveitis
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.6.1. Institutional Sales
  • 9.6.2. Retail Pharmacies
  • 9.6.3. Mail Order Pharmacies
  • 9.6.4. Retail Sales
• 9.7. Market Attractiveness Analysis

10. Latin America Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Indication
  • 10.2.4. By Distribution Channel
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 10.4.1. VEGF-A Antagonists
  • 10.4.2. TNF-a Inhibitors
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 10.5.1. Macular Degeneration
  • 10.5.2. Diabetic Macular Edema
  • 10.5.3. Diabetic Retinopathy
  • 10.5.4. Uveitis
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.6.1. Institutional Sales
  • 10.6.2. Retail Pharmacies
  • 10.6.3. Mail Order Pharmacies
  • 10.6.4. Retail Sales
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Retinal Biologics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Indication
  • 11.2.4. By Distribution Channel
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 11.4.1. VEGF-A Antagonists
  • 11.4.2. TNF-a Inhibitors
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
  • 11.5.1. Macular Degeneration
  • 11.5.2. Diabetic Macular Edema
  • 11.5.3. Diabetic Retinopathy
  • 11.5.4. Uveitis
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.6.1. Institutional Sales
  • 11.6.2. Retail Pharmacies
  • 11.6.3. Mail Order Pharmacies
  • 11.6.4. Retail Sales
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Spark Therapeutics, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. F. Hoffmann-La Roche Ltd.
    • 12.3.2.1.Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Regeneron Pharmaceuticals, Inc.
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. AbbVie Inc.
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Amgen Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Novartis Pharma AG
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. MeiraGTx Limited
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Oxurion NV
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Santen Pharmaceutical Co., Ltd.
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Bayer AG
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Bausch Health Companies Inc.
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Merck & Co., Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Adverum Biotechnologies
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations